JP2015505843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505843A5 JP2015505843A5 JP2014546255A JP2014546255A JP2015505843A5 JP 2015505843 A5 JP2015505843 A5 JP 2015505843A5 JP 2014546255 A JP2014546255 A JP 2014546255A JP 2014546255 A JP2014546255 A JP 2014546255A JP 2015505843 A5 JP2015505843 A5 JP 2015505843A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- biologically active
- pharmaceutical composition
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576034P | 2011-12-15 | 2011-12-15 | |
| US61/576,034 | 2011-12-15 | ||
| PCT/CA2012/050899 WO2013086636A1 (en) | 2011-12-15 | 2012-12-14 | Soluble igf receptor fc fusion proteins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015505843A JP2015505843A (ja) | 2015-02-26 |
| JP2015505843A5 true JP2015505843A5 (enExample) | 2016-02-04 |
Family
ID=48611766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546255A Pending JP2015505843A (ja) | 2011-12-15 | 2012-12-14 | 可溶性ＩＧＦレセプターＦｃ融合タンパク質およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10538575B2 (enExample) |
| EP (1) | EP2791338B1 (enExample) |
| JP (1) | JP2015505843A (enExample) |
| KR (1) | KR20150031217A (enExample) |
| CN (1) | CN104066845A (enExample) |
| BR (1) | BR112014014418A2 (enExample) |
| CA (1) | CA2858389A1 (enExample) |
| HK (1) | HK1202587A1 (enExample) |
| WO (1) | WO2013086636A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP7095992B2 (ja) * | 2014-12-08 | 2022-07-05 | １グローブ バイオメディカル カンパニー， リミテッド | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
| ES2834823T3 (es) * | 2015-06-04 | 2021-06-18 | Ospedale San Raffaele Srl | IGFBP3 y usos del mismo |
| AU2016272045B2 (en) * | 2015-06-04 | 2018-04-19 | Ospedale San Raffaele Srl | Inhibitor of IGFBP3/TMEM219 axis and diabetes |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP7106187B2 (ja) | 2016-05-11 | 2022-07-26 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを保存する方法 |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| ES2874974T3 (es) | 2016-05-11 | 2021-11-05 | Cytiva Bioprocess R & D Ab | Matriz de separación |
| ES2909833T3 (es) | 2016-05-11 | 2022-05-10 | Cytiva Bioprocess R & D Ab | Método de limpieza y/o desinfección de una matriz de separación |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| CN106520806B (zh) * | 2016-11-03 | 2018-06-19 | 宜明细胞生物科技有限公司 | 一种重组car基因及其载体、car-t细胞和应用 |
| EP3632929A1 (en) | 2018-10-02 | 2020-04-08 | Ospedale San Raffaele S.r.l. | Antibodies and uses thereof |
| CN113092392B (zh) * | 2021-03-05 | 2022-11-08 | 苏州西山中科药物研究开发有限公司 | 一种检测猴血清中靶向可溶性蛋白的单克隆抗体药物总浓度的通用型方法 |
| CN119708266B (zh) * | 2025-02-26 | 2025-06-06 | 首玺(广州)医疗科技有限责任公司 | 一种胰岛素样生长因子-1连接多肽及其在子宫内膜损伤修复中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0861267A4 (en) | 1995-11-14 | 2000-02-02 | Univ Jefferson | INDUCTION AND RESISTANCE TO TUMOR GROWTH BY MEANS OF SOLUBLE IGF-1 |
| PT1699822E (pt) * | 2003-12-30 | 2008-07-30 | Merck Patent Gmbh | Proteínas de fusão de il-7 |
| MY146381A (en) * | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| US7713521B2 (en) * | 2005-08-12 | 2010-05-11 | Schering Corporation | MCP1 fusions |
| TW200722436A (en) * | 2005-10-21 | 2007-06-16 | Hoffmann La Roche | A peptide-immunoglobulin-conjugate |
| JP2010518140A (ja) * | 2007-02-14 | 2010-05-27 | グラクソ グループ リミテッド | Ｉｇｆ−１ｒに対する新規抗体 |
| GB0702888D0 (en) * | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
| AU2008223541B2 (en) | 2007-03-02 | 2012-04-05 | Amgen Inc. | Methods and compositions for treating tumor diseases |
| AU2008281801A1 (en) | 2007-08-01 | 2009-02-05 | Glaxo Group Limited | Novel antibodies |
| KR20110044992A (ko) * | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | ＴＧＦ-β 길항제 다중-표적 결합 단백질 |
| CN102171247A (zh) | 2008-07-02 | 2011-08-31 | 特鲁比昂药品公司 | TNF-α拮抗剂多靶点结合蛋白 |
| JP2011529452A (ja) * | 2008-07-29 | 2011-12-08 | ザ・ロイヤル・インスティテューション・フォア・ザ・アドバンスメント・オブ・ラーニング／マクギル・ユニヴァーシティ | 抗血管新生薬としての可溶性ｉｇｆ受容体 |
| DK2352763T4 (da) * | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
| EP2435477A1 (en) * | 2009-05-28 | 2012-04-04 | Glaxo Group Limited | Antigen-binding proteins |
-
2012
- 2012-12-14 WO PCT/CA2012/050899 patent/WO2013086636A1/en not_active Ceased
- 2012-12-14 CN CN201280067765.6A patent/CN104066845A/zh active Pending
- 2012-12-14 HK HK15103272.6A patent/HK1202587A1/xx unknown
- 2012-12-14 CA CA2858389A patent/CA2858389A1/en not_active Abandoned
- 2012-12-14 US US14/365,250 patent/US10538575B2/en active Active
- 2012-12-14 KR KR20147019486A patent/KR20150031217A/ko not_active Withdrawn
- 2012-12-14 JP JP2014546255A patent/JP2015505843A/ja active Pending
- 2012-12-14 EP EP12857915.8A patent/EP2791338B1/en active Active
- 2012-12-14 BR BR112014014418A patent/BR112014014418A2/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Corre et al. | The osteosarcoma microenvironment: a complex but targetable ecosystem | |
| Feldman | Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments | |
| Qazi et al. | Cotargeting ephrin receptor tyrosine kinases A2 and A3 in cancer stem cells reduces growth of recurrent glioblastoma | |
| Yu et al. | Potential approaches to the treatment of Ewing's sarcoma | |
| JP2021063120A (ja) | 癌を処置するための併用方法 | |
| Caffo et al. | Innovative therapeutic strategies in the treatment of brain metastases | |
| JP2015529641A5 (enExample) | ||
| JP2018521135A5 (enExample) | ||
| CN112867503A (zh) | 掩蔽的细胞因子缀合物 | |
| JP2017171685A5 (enExample) | ||
| RU2018105985A (ru) | Новый подход к лечению рака с применением иммуномодуляции | |
| EA200701250A1 (ru) | Иммуноконъюгаты против интегрина, способы и варианты применения | |
| JP2016535009A5 (enExample) | ||
| JP2016502515A5 (enExample) | ||
| US20220056450A1 (en) | Rna nanostructures and methods of making and using rna nanostructures | |
| JP2017534259A5 (enExample) | ||
| JP2019506862A5 (enExample) | ||
| EA201792103A1 (ru) | Композиции и способы для ингибирования экспрессии генов hif2альфа | |
| Zhao et al. | IL10-modified human mesenchymal stem cells inhibit pancreatic cancer growth through angiogenesis inhibition | |
| JP2023532032A (ja) | 血液脳関門浸透アプタマー及びその利用 | |
| JP2018509423A5 (enExample) | ||
| JP2014525412A5 (enExample) | ||
| Lu et al. | Cancer-associated fibroblasts: central players in cancer hallmarks and therapeutic resistance | |
| EP2545171A4 (en) | HJURP PEPTIDES AND VACCINES CONTAINING THEM | |
| Tognolini et al. | Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018–present) |